Key facts
- STRM.BIO’s last known valuation is $26.0M (Mar 2021).
- It has raised $25.2M; the latest was Seed Round ($8.0M) in Jan 2026.
- Notable investors include Calm Ventures, Gates Foundation, The Engine, Boehringer Ingelheim Venture Fund, Ascension Ventures — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for STRM.BIO
- ·The full record, as it builds
Funding rounds
No funding rounds for STRM.BIO are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About STRM.BIO
Developer of a non-viral in vivo gene delivery platform designed to enable targeted transport of genetic material to bone marrow cells for therapeutic research and development. The company's platform is built on cell-derived extracellular vesicle technology capable of carrying deoxyribonucleic acid, ribonucleic acid, and protein cargos, supporting repeat dosing, scalable manufacturing, tunable tissue targeting, and preferential biodistribution to bone marrow while avoiding off-target organs, enabling biopharmaceutical researchers and clinical development groups focused on hematologic and immune-related diseases to advance precise in vivo cell and gene therapy programs with improved delivery control and biological compatibility
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2019
- Employees
- 16
- Website
- strm.bio/
- Ownership
- Privately Held (backing)
STRM.BIO doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in STRM.BIO shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on STRM.BIO in its N-PORT filings yet. We sweep new filings monthly.